Connect Biopharma Holdings (CNTB) Revenue (2024 - 2026)

Connect Biopharma Holdings (CNTB) posted Revenue of $169000.0 for Q1 2026, up 956.25% sequentially from $16000.0 in Q3 2025.

Connect Biopharma Holdings (CNTB) Revenue (2024 - 2026) Analysis & Trends

Connect Biopharma Holdings has reported Revenue for 3 years, with the latest figure at $169000.0 in Q1 2026.

Quarterly Revenue changed N/A year-over-year to $169000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $233000.0 (changed N/A YoY) and the FY2025 annual result came in at $64000.0, down 99.75% from the prior year.
Revenue grew to $169000.0 in Q1 2026 per CNTB's latest filing, from $16000.0 in the prior quarter.
Over five years, Revenue peaked at $1.2 million in Q3 2024 and troughed at $16000.0 in Q3 2025.
A 3-year average of $430000.0 and a median of $169000.0 in 2026 frame the typical range for Revenue.
The widest YoY moves for Revenue: up 98.69% in 2025, down 98.69% in 2025.
Over 3 years, Revenue stood at $698000.0 in 2024, then slumped by 97.71% to $16000.0 in 2025, then surged by 956.25% to $169000.0 in 2026.
According to Business Quant data, Revenue over the past three periods registered $169000.0, $16000.0, and $48000.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	1.52 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	145.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	1.71 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	1.29 Bn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	425.49 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	674.14 Mn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	1.06 Bn
10	Connect Biopharma Holdings	144.32 Mn	144.32 Mn	-	2.77 Mn

Download Data